Illumina, Inc. (NASDAQ:ILMN) Shares Sold by DF Dent & Co. Inc.

DF Dent & Co. Inc. decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 11.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 108,418 shares of the life sciences company’s stock after selling 13,397 shares during the quarter. DF Dent & Co. Inc. owned approximately 0.07% of Illumina worth $14,488,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Huntington National Bank grew its holdings in Illumina by 279.4% in the fourth quarter. Huntington National Bank now owns 1,954 shares of the life sciences company’s stock valued at $261,000 after purchasing an additional 1,439 shares during the period. Scholtz & Company LLC purchased a new position in Illumina during the fourth quarter worth approximately $2,844,000. Groupama Asset Managment boosted its holdings in shares of Illumina by 12.9% in the 4th quarter. Groupama Asset Managment now owns 5,082 shares of the life sciences company’s stock valued at $679,000 after purchasing an additional 579 shares during the last quarter. Trexquant Investment LP grew its stake in shares of Illumina by 16.7% during the 4th quarter. Trexquant Investment LP now owns 142,977 shares of the life sciences company’s stock valued at $19,106,000 after buying an additional 20,506 shares during the period. Finally, HighPoint Advisor Group LLC increased its holdings in shares of Illumina by 15.9% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,121 shares of the life sciences company’s stock worth $283,000 after buying an additional 291 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 4.5 %

Shares of NASDAQ:ILMN opened at $81.88 on Thursday. Illumina, Inc. has a 12-month low of $77.54 and a 12-month high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a market cap of $12.97 billion, a PE ratio of -10.66, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a fifty day simple moving average of $99.22 and a 200 day simple moving average of $125.82.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on ILMN. Canaccord Genuity Group reduced their target price on Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, March 11th. HSBC lowered Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a research note on Friday, February 28th. Robert W. Baird dropped their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, March 5th. Morgan Stanley reduced their price target on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. Finally, Stephens reiterated an “overweight” rating and set a $156.00 price objective on shares of Illumina in a research note on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.